Omnimmune Holdings, Inc. (OMMH) Stock Analysis
DELISTED 2026
What happened to Omnimmune Holdings, Inc. (OMMH) stock?
Omnimmune Holdings, Inc. (OMMH) no longer trades on public markets. It was delisted in May 2026. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Omnimmune Holdings, Inc. (OMMH) trades at $0.0001. Omnimmune Holdings, Inc. is a development-stage biotechnology company focused on integrating cancer therapeutic, diagnostic, and prognostic technologies. The company aims to develop personalized cancer treatments targeting human chorionic gonadotropin. Sector: Healthcare.
Last analyzed: Mar 17, 2026Analyst Coverage for OMMH: OMMH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OMMH against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
OMMH: the 2 scored disciplines are evenly split. Dominant signal: Ray Dalio bullish.
How is this calculated? →Omnimmune Holdings, Inc. (OMMH) Healthcare & Pipeline Overview
Omnimmune Holdings, Inc., a development-stage biotechnology firm, focuses on personalized cancer treatments using monoclonal antibody technologies and genomic-based products. The company is based in Houston, Texas, and is preparing for a Phase I trial of its lead candidate, anti-human chorionic gonadotropin beta subunit monoclonal antibodies, in the competitive biotechnology sector.
What Is the Investment Thesis for OMMH?
Omnimmune Holdings, Inc. presents a high-risk, high-reward investment opportunity characteristic of early-stage biotechnology companies. The company's focus on personalized cancer treatments and monoclonal antibody technologies could yield significant returns if clinical trials are successful. The planned Phase I trial for its lead candidate, anti-human chorionic gonadotropin beta subunit monoclonal antibodies, is a key catalyst to watch. However, the company's limited operating history, small size (2 employees), and OTC listing introduce substantial risks. Investors should carefully consider the speculative nature of this investment and the potential for dilution or failure to achieve clinical milestones. Successful completion of the Phase I trial and subsequent advancement through the clinical pipeline are critical for realizing value.
Based on FMP financials and quantitative analysis
OMMH Key Highlights
Omnimmune Holdings, Inc. is a development-stage biotechnology company focused on cancer therapeutics.
- The company's lead candidate is anti-human chorionic gonadotropin beta subunit monoclonal antibodies.
- Omnimmune plans to conduct a Phase I trial based on the results of its diagnostic trial.
- The company is based in Houston, Texas.
- Omnimmune Holdings, Inc. has a market capitalization of $0.00B as of 2026-03-17.
Who Are OMMH's Competitors?
OMMH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OMMH's Key Strengths?
Proprietary monoclonal antibody technologies.
- Focus on personalized cancer treatments.
- Potential for targeted therapies with fewer side effects.
- Planned Phase I trial for lead candidate.
What Are OMMH's Weaknesses?
Development-stage company with limited operating history.
- Small size and limited resources (2 employees).
- Dependence on a single lead candidate.
- OTC listing, which may limit access to capital.
What Could Drive OMMH Stock Higher?
Planned Phase I trial for anti-human chorionic gonadotropin beta subunit monoclonal antibodies.
- Research and development efforts to expand the product pipeline.
- Pursuit of strategic partnerships and collaborations.
- Exploration of potential acquisitions of complementary technologies.
What Are the Key Risks for OMMH?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to achieve positive results in the Phase I trial.
- Regulatory delays or rejection of the company's treatments.
- Competition from larger, more established biotechnology companies.
- Difficulty in securing funding for research and development.
- Limited operating history and small size of the company.
What Are the Growth Opportunities for OMMH?
- Advancement of Lead Candidate: Omnimmune's primary growth opportunity lies in the successful development and commercialization of its lead candidate, anti-human chorionic gonadotropin beta subunit monoclonal antibodies. The planned Phase I trial is a critical milestone. Positive results could lead to further clinical trials, potential partnerships, and eventual FDA approval. The market for targeted cancer therapies is substantial, offering significant revenue potential if the treatment proves effective and safe. The timeline for this growth opportunity is dependent on the successful completion of clinical trials, which typically take several years.
- Expansion of Product Pipeline: Omnimmune has the opportunity to expand its product pipeline beyond its lead candidate. By leveraging its monoclonal antibody technologies and genomic-based products, the company could develop additional personalized cancer treatments. This expansion could involve targeting different types of cancer or developing new diagnostic tools. A broader product pipeline would reduce the company's reliance on a single product and increase its overall value. The timeline for this growth opportunity is dependent on research and development efforts and the availability of funding.
- Strategic Partnerships and Collaborations: Omnimmune could pursue strategic partnerships and collaborations with other biotechnology or pharmaceutical companies. These partnerships could provide access to additional funding, expertise, and resources. Collaborations could also accelerate the development and commercialization of Omnimmune's products. The biotechnology industry is characterized by frequent collaborations, and successful partnerships can be a key driver of growth. The timeline for this growth opportunity is dependent on the company's ability to identify and secure suitable partners.
- Acquisition of Complementary Technologies: Omnimmune could grow through the acquisition of complementary technologies or companies. This could involve acquiring new diagnostic tools, therapeutic approaches, or intellectual property. Acquisitions could expand the company's capabilities and strengthen its competitive position. The biotechnology industry is characterized by frequent mergers and acquisitions, and strategic acquisitions can be a key driver of growth. The timeline for this growth opportunity is dependent on the availability of suitable acquisition targets and the company's ability to secure funding.
- Out-Licensing or Sale of Technologies: Omnimmune could generate revenue by out-licensing or selling its technologies to other companies. This could involve licensing its monoclonal antibody technologies or selling its intellectual property. Out-licensing or sales could provide a source of non-dilutive funding and allow the company to focus on its core areas of expertise. The biotechnology industry is characterized by frequent licensing agreements, and successful out-licensing or sales can be a key driver of value. The timeline for this growth opportunity is dependent on the market demand for the company's technologies.
What Are OMMH's Competitive Advantages?
- Proprietary monoclonal antibody technologies.
- Focus on personalized cancer treatments.
- Intellectual property rights related to its technologies.
- Potential first-mover advantage in targeting human chorionic gonadotropin.
What Does OMMH Do?
Omnimmune Holdings, Inc., through its subsidiary Omnimmune Corp., is a development-stage biotechnology company based in Houston, Texas. The company is focused on integrating cancer therapeutic, diagnostic, and prognostic technologies. Omnimmune owns rights for monoclonal antibody technologies and intends to develop personalized cancer treatments. These treatments involve the selection of prophylactic and therapeutic vaccines (active immunization), monoclonal antibodies (passive immunization), and genomic-based products, all targeting a hormone called human chorionic gonadotropin. The company's primary focus is on developing personalized cancer treatments. This approach involves identifying and selecting the most effective combination of vaccines, antibodies, and genomic-based products for each patient. By targeting human chorionic gonadotropin, a hormone associated with certain cancers, Omnimmune aims to create treatments that are both effective and have minimal side effects. Omnimmune plans to conduct a Phase I trial with its lead candidate, anti-human chorionic gonadotropin beta subunit monoclonal antibodies, based on the results of its diagnostic trial. This trial will be a crucial step in evaluating the safety and efficacy of the company's lead candidate.
What Products and Services Does OMMH Offer?
- Develops personalized cancer treatments.
- Integrates cancer therapeutic, diagnostic, and prognostic technologies.
- Owns rights for monoclonal antibody technologies.
- Selects prophylactic and therapeutic vaccines (active immunization).
- Utilizes monoclonal antibodies (passive immunization).
- Develops genomic-based products.
- Targets human chorionic gonadotropin.
How Does OMMH Make Money?
- Develops and patents cancer treatment technologies.
- Conducts clinical trials to validate treatment efficacy.
- Seeks regulatory approval for its treatments.
- Potentially licenses or sells its technologies to other companies.
What Industry Does OMMH Operate In?
Omnimmune Holdings, Inc. operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory hurdles. The market for cancer therapeutics is substantial and growing, driven by an aging population and increasing cancer incidence rates. Personalized medicine, the focus of Omnimmune's approach, is a key trend in the industry. Competitors include companies like ADYX (Adynxx, Inc.), ATRX (Atrionix, Inc.), CFRXQ (ContraFect Corporation), DMKPQ (Digimarc Corporation), and EFTR (Eleftera S.A.), each pursuing different approaches to cancer treatment. Success in this industry requires strong scientific expertise, effective clinical trial execution, and the ability to navigate complex regulatory pathways.
Who Are OMMH's Key Customers?
- Potentially cancer patients seeking personalized treatment options.
- Pharmaceutical companies interested in licensing or acquiring Omnimmune's technologies.
- Healthcare providers looking for innovative cancer therapies.
Financial Health
Omnimmune Holdings, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Key Financial Metrics
Return on equity for Omnimmune Holdings, Inc. stands at 38.4%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.01 means current liabilities exceed short-term assets, a liquidity point worth watching.
Company Profile
Omnimmune Holdings, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Houston, US. The company is led by CEO Saul Leal. OMMH has traded publicly since 2007.
OMMH Financials
Bull Case vs Bear Case
Bull Case
- Proprietary monoclonal antibody technologies.
- Focus on personalized cancer treatments.
- Potential for targeted therapies with fewer side effects.
- Planned Phase I trial for lead candidate.
Bear Case
- Development-stage company with limited operating history.
- Small size and limited resources (2 employees).
- Dependence on a single lead candidate.
- OTC listing, which may limit access to capital.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
OMMH Latest News
No recent news available for OMMH.
Leadership: Howard Becker
Unknown
Information on Howard Becker's background is not available. His role at Omnimmune Holdings involves managing a small team of 2 employees. Further details regarding his career history, education, and previous roles are unknown.
Track Record: Due to the limited information available, Howard Becker's track record and key achievements at Omnimmune Holdings are unknown. The company is in the early stages of development, and there are no publicly available milestones to assess his leadership.
OMMH OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Omnimmune Holdings, Inc. may not meet the minimum financial standards or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial reporting and may not be subject to the same level of regulatory scrutiny as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure and transparency.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's legal and regulatory compliance.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Company's registration and legal standing.
- Existence of a physical headquarters and contact information.
- Presence of a professional website and investor relations materials.
- Independent audits of financial statements (if available).
- Press releases and news coverage about the company.
Omnimmune Holdings, Inc. Healthcare Stock: Key Questions Answered
What happened to Omnimmune Holdings, Inc. (OMMH) stock?
Omnimmune Holdings, Inc. (OMMH) no longer trades on public markets. It was delisted in May 2026. The figures below are historical and are not a current quote.
Can I still buy OMMH shares?
No. OMMH stopped trading on public markets in May 2026, so the shares are not available through a broker. Anything you see quoted for OMMH elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before OMMH stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Omnimmune Holdings, Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Omnimmune Holdings, Inc. do?
Omnimmune Holdings, Inc. is a development-stage biotechnology company focused on creating personalized cancer treatments. Through its subsidiary, Omnimmune Corp., the company integrates therapeutic, diagnostic, and prognostic technologies to target human chorionic gonadotropin. Their approach involves using vaccines, monoclonal antibodies, and genomic-based products tailored to individual patients.
What do analysts say about OMMH stock?
As of 2026-03-17, there is no available analyst coverage for Omnimmune Holdings, Inc. This lack of coverage is typical for early-stage, OTC-listed biotechnology companies. Investors should conduct their own thorough due diligence and consider the high-risk, high-reward nature of this investment. Key valuation metrics are currently unavailable due to the company's development stage and lack of revenue.
What are the main risks for OMMH?
Investing in Omnimmune Holdings, Inc. carries significant risks inherent to early-stage biotechnology companies and OTC-listed stocks. The company's success depends heavily on the outcome of its Phase I trial, and failure to achieve positive results could severely impact its value. Regulatory hurdles and competition from larger companies pose additional challenges.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is limited due to the company's development stage and OTC listing.
- Financial data is based on available public information and may be incomplete.